A low-frequency Ki67+ subclone may initiate the tumor and then persist throughout treatment by generating a cellular hierarchy, with cells endowed with a Ki67-driven self-renewal phenotype being able to escape such therapies and reemerge to initiate tumor relapse (48). This evidence concerns the gene MKI67 and neoplasm.